【摘要】：綜述帕比司他聯(lián)合硼替佐米和地塞米松治療前期至少2種治療方案(硼替佐米聯(lián)合免疫調(diào)節(jié)劑)失敗的多發(fā)性骨髓瘤(MM)的新治療方案的作用機(jī)制、藥效學(xué)、藥動(dòng)學(xué)、臨床評(píng)價(jià)和安全性。本品作為組蛋白去乙�；敢种苿�(HDACi),對(duì)復(fù)發(fā)/難治型MM具有較高活性。動(dòng)物實(shí)驗(yàn)和臨床試驗(yàn)結(jié)果顯示本品對(duì)MM有很好的療效,但需關(guān)注其藥物不良反應(yīng)和藥物間相互作用。帕比司他可增加無(wú)進(jìn)展生存期(PFS)并且更益于MM治療,是MM患者的又一治療選擇。
[Abstract]:To review the mechanism, pharmacodynamics and pharmacokinetics of at least two new protocols (bortezomil combined with immunomodulator) for the treatment of failed multiple myeloma (MM) in the early stage of treatment of multiple myeloma (MM) with parbesmast combined with bortezomil and dexamethasone (Dexamethasone). Clinical evaluation and safety. (HDACi), a histone deacetylase inhibitor, has high activity for recurrent / refractory MM. The results of animal and clinical trials showed that the drug had a good effect on MM, but attention should be paid to its adverse drug reactions and drug interactions. Pabestat can increase (PFS) and be more beneficial to MM treatment, which is an alternative treatment for MM patients.
【作者單位】： 中國(guó)醫(yī)學(xué)科學(xué)院北京協(xié)和醫(yī)院藥劑科;北京市昌平區(qū)中西醫(yī)結(jié)合醫(yī)院藥劑科;
【分類號(hào)】：R979.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前7條

1 劉蕾;白硯霞;;硼替佐米臨床研究進(jìn)展[J];臨床薈萃;2009年08期

2 紀(jì)安成;韓航;王超群;張愛(ài)華;;硼替佐米的合成工藝改進(jìn)[J];藥學(xué)與臨床研究;2014年02期

3 叢艷偉;欒春芳;陳宏;張琪;白p楻，

本文編號(hào)：2182691